Thus, the unexpected association between tAXL expression and ICI-responsiveness observed in this study may be driven by oncogenic variants in genes such as MUC4 and KRAS that elicit neoantigen-specific anti-tumor immune responses, prompting AXL/PD-L1-upregulation and priming tumors to respond to ICIs. This evidence concerns the gene AXL and neoplasm.